---
title: "Boan Biotech Wins New China Approval for Denosumab Biosimilar, Accelerates Global Push"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287581709.md"
description: "Shandong Boan Biotechnology has received approval from China's National Medical Products Administration for its denosumab biosimilar, Boluojia, to treat bone metastases. This expands its use beyond giant cell tumor of bone and enhances its oncology portfolio. The company aims to leverage this approval for international expansion, targeting markets in the U.S., Southeast Asia, and Latin America, supported by strong clinical data and a growing global market for denosumab therapies."
datetime: "2026-05-26T04:37:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287581709.md)
  - [en](https://longbridge.com/en/news/287581709.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287581709.md)
---

# Boan Biotech Wins New China Approval for Denosumab Biosimilar, Accelerates Global Push

### Meet Samuel – Your Personal Investing Prophet

-   Start a conversation with TipRanks’ trusted, data-backed investment intelligence
-   Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds

Shandong Boan Biotechnology Company., Limited. Class H ( (HK:6955) ) just unveiled an update.

Shandong Boan Biotechnology has received approval from China’s National Medical Products Administration for a new indication of its denosumab biosimilar Boluojia, allowing its use to delay or reduce skeletal-related events in patients with bone metastases from solid tumors or multiple myeloma. This expands on Boluojia’s initial Chinese approval for giant cell tumor of bone and positions the drug as a clinically validated, guideline-recommended option with practical advantages such as subcutaneous administration and suitability for patients with renal impairment.

The company is leveraging this approval to strengthen its oncology portfolio in mainland China and accelerate international expansion through a mix of in-house commercialization and partnerships, including deals covering the U.S., Southeast Asia, Latin America, Hong Kong, and Macao. With robust clinical data showing high similarity to reference drug Xgeva and a large, growing global market for denosumab therapies, the new indication is expected to enhance Boan’s competitive position and open meaningful revenue opportunities in both domestic and overseas markets.

**More about Shandong Boan Biotechnology Company., Limited. Class H**

Shandong Boan Biotechnology Co., Ltd. is a Chinese biopharmaceutical company specializing in the development and commercialization of biosimilars and innovative biologics, with a strong focus on oncology. Its portfolio includes products such as Boluojia (denosumab injection) and Boyounuo (bevacizumab injection), and it is pursuing a global strategy across China, Europe, the U.S., Japan, and emerging markets.

**Average Trading Volume:** 6,132,000

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$3.77B

For a thorough assessment of 6955 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [06955.HK](https://longbridge.com/en/quote/06955.HK.md)

## Related News & Research

- [Duality Biotherapeutics Wins SSE Acceptance for Planned RMB Share Issue](https://longbridge.com/en/news/289622748.md)
- [Is Interface (TILE) Quietly Recasting Its Brand Around Biophilic, PVC-Free Flooring Innovation?](https://longbridge.com/en/news/289626870.md)
- [Shift in biosimilar commercial landscape essential for sector sustainability, expert says](https://longbridge.com/en/news/289174897.md)
- [Beijing Biostar Pharmaceuticals Withdraws Three Resolutions From 2026 AGM Agenda](https://longbridge.com/en/news/289522789.md)
- [AFYREN’s Impact-Driven Bioeconomy Model Confirmed by B Corp™ Certification](https://longbridge.com/en/news/289278937.md)